Research & Publications

Research abstract: Obesity Care Management Program 6-Month Outcomes and Glucagon-Like Peptide-1 (GLP-1) Therapy Persistence Among Commercially Insured Adults Without Diabetes

Prime study finds individuals enrolled in the program for six months who took GLP-1 drugs for obesity lost an average of 22.5 pounds, and 95% of patients remained on GLP-1 therapy

Research abstract

About Prime Therapeutics

Prime Therapeutics logo

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn

Latest News